EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19

Henrik Berg Rasmussen, Peter Riis Hansen iD

Viruses · 25.10.2023 · 15 (11) · 2151

DOI: 10.3390/v15112151 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 25.10.2023. Verfasst von Henrik Berg Rasmussen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biological Psychiatry, Mental Health Centre Sct. Hans, 4000 Roskilde, Denmark. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Molnupiravir, a prodrug known for its broad antiviral activity, has demonstrated efficacy in animal models of COVID-19, prompting clinical trials, in which initial results indicated a significant effect against the disease. However, subsequent clinical studies did not confirm these findings, leading to the refusal of molnupiravir for permanent market authorization in many countries. This report critically assessed 22 studies published in 18 reports that investigated the efficacy of molnupiravir in animal models of COVID-19, with the purpose of determining how well the design of these models informed human studies. We found that the administered doses of molnupiravir in most studies involving animal COVID-19 models were disproportionately higher than the dose recommended for human use. Specifically, when adjusted for body surface area, over half of the doses of molnupiravir used in the animal studies exceeded twice the human dose. Direct comparison of reported drug exposure across species after oral administration of molnupiravir indicated that the antiviral efficacy of the dose recommended for human use was underestimated in some animal models and overestimated in others. Frequently, molnupiravir was given prophylactically or shortly after SARS-CoV-2 inoculation in these models, in contrast to clinical trials where such timing is not consistently achieved. Furthermore, the recommended five-day treatment duration for humans was exceeded in several animal studies. Collectively, we suggest that design elements in the animal studies under examination contributed to a preference favoring molnupiravir, and thus inflated expectations for its efficacy against COVID-19. Addressing these elements may offer strategies to enhance the clinical efficacy of molnupiravir for the treatment of COVID-19. Such strategies include dose increment, early treatment initiation, administration by inhalation, and use of the drug in antiviral combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19AnimalsHumansSARS-CoV-2Models, AnimalAntiviral AgentsCytidineHydroxylamines

Stichwörter der Autor:innen

COVID-19animal modelsanimal-to-human extrapolationantiviral efficacymolnupiravir

Substanzen

Antiviral AgentsmolnupiravirCytidineHydroxylamines

Autor:innen und Institutionen

  • Institute of Biological Psychiatry, Mental Health Centre Sct. Hans, 4000 Roskilde, Denmark.
  • Department of Science and Environment, Roskilde University, 4000 Roskilde, Denmark.
  • Department of Cardiology, Herlev and Gentofte Hospital, Copenhagen University Hospital, 2900 Hellerup, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.

ORCID-Profile: Peter Riis Hansen

Zitieren

APA

Rasmussen, H. B., & Hansen, P. R. (2023). Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19. Viruses, 15(11), 2151. https://doi.org/10.3390/v15112151

Vancouver

Rasmussen HB, Hansen PR. Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19. Viruses. 2023;15(11):2151. doi:10.3390/v15112151

BibTeX
@article{Rasmussen2023,
  author = {Rasmussen, Henrik Berg and Hansen, Peter Riis},
  title = {Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19},
  journal = {Viruses},
  year = {2023},
  volume = {15},
  number = {11},
  pages = {2151},
  doi = {10.3390/v15112151}
}
Kostenlos starten →